Dark Energy from Mass Varying Neutrinos

We show that mass varying neutrinos (MaVaNs) can behave as a negative pressure fluid which could be the origin of the cosmic acceleration. We derive a model independent relation between the neutrino mass and the equation of state parameter of the neutrino dark energy, which is applicable for general theories of mass varying particles. The neutrino mass depends on the local neutrino density and the observed neutrino mass can exceed the cosmological bound on a constant neutrino mass. We discuss microscopic realizations of the MaVaN acceleration scenario, which involve a sterile neutrino. We consider naturalness constraints for mass varying particles, and find that both ev cutoffs and ev mass particles are needed to avoid fine-tuning. These considerations give a (current) mass of order an eV for the sterile neutrino in microscopic realizations, which could be detectable at MiniBooNE. Because the sterile neutrino was much heavier at earlier times, constraints from big bang nucleosynthesis on additional states are not problematic. We consider regions of high neutrino density and find that the most likely place today to find neutrino masses which are significantly different from the neutrino masses in our solar system is in a supernova. The possibility of different neutrino mass in different regions of the galaxy and the local group could be significant for Z-burst models of ultra-high energy cosmic rays. We also consider the cosmology of and the constraints on the ``acceleron'', the scalar field which is responsible for the varying neutrino mass, and briefly discuss neutrino density dependent variations in other constants, such as the fine structure constant.Comment: 26 pages, 3 figures, refs added, typos corrected, comment added about possible matter effect

Detection of thermal neutrons with the PRISMA-YBJ array in extensive air showers selected by the ARGO-YBJ experiment

We report on a measurement of thermal neutrons, generated by the hadronic component of extensive air showers (EAS), by means of a small array of EN-detectors developed for the PRISMA project (PRImary Spectrum Measurement Array), novel devices based on a compound alloy of ZnS(Ag) and (LiF)-Li-6. This array has been operated within the ARGO-YBJ experiment at the high altitude Cosmic Ray Observatory in Yangbajing (Tibet, 4300 m a.s.l.). Due to the tight correlation, between the air shower hadrons and thermal neutrons, this technique can be envisaged as a simple way to estimate the number of high energy hadrons in EAS. Coincident events generated by primary cosmic rays of energies greater than 100 TeV have been selected and analyzed. The EN-detectors have been used to record simultaneously thermal neutrons and the air shower electromagnetic component. The density distributions of both components and the total number of thermal neutrons have been measured. The correlation of these data with the measurements carried out by ARGO-YBJ confirms the excellent performance of the EN-detector. (C) 2016 Elsevier B.V. All rights reserved

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Multiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits. © 2018 The Author